Differences in Motor Features of C9orf72, MAPT, or GRN Variant Carriers With Familial Frontotemporal Lobar Degeneration.
Philip Wade Tipton, Angela B Deutschlaender, Rodolfo Savica...
https://pubmed.ncbi.nlm.nih.gov/35790423/Actively Recruiting
Led by Mayo Clinic · Updated on 2026-10-07
2100
Participants Needed
26
Research Sites
N/A
Total Duration
Researchers are studying frontotemporal lobar degeneration FTLD, including its sporadic and familial forms, as well as asymptomatic family members of those with familial FTLD. This study aims to better understand the condition over time, helping to shape future clinical trials. It integrates two prior research efforts into a single North American consortium focused on FTLD and related syndromes. Participants join one of two study groups the longitudinal arm or the biofluid-focused arm. The longitudinal arm involves yearly comprehensive assessments including clinical evaluations, functional testing, brain imaging, and collection of biological samples. The biofluid-focused arm consists of a single clinic visit with limited clinical data collection alongside biospecimen sampling. These approaches help capture a broad range of information on FTLD progression. During the study, participants undergo regular evaluations to measure brain volume changes, neuropsychological function, and multidomain impairment using specific rating scales over up to five years. Blood samples are also analyzed for biomarkers such as plasma neurofilament light chain. The study is observational, with participants being monitored annually or once depending on their group, and may continue for several years to gather long-term data on disease progression and related outcomes.
CONDITIONS
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
L
Leah K Forsberg, PhD
H
Hilary Heuer, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Mayo Clinic
Lead Sponsor
University of California, San Francisco
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 10 years
Participants undergo annual clinic visits involving detailed clinical, functional, imaging, and biofluid assessments to monitor disease progression over time.
Annual visits
Duration - Single visit
Participants complete a single clinic visit with clinical data collection and biospecimen sampling focused on biofluid analysis.
1 visit (in-person)
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Philip Wade Tipton, Angela B Deutschlaender, Rodolfo Savica...
https://pubmed.ncbi.nlm.nih.gov/35790423/Mayo Clinic
Lead Sponsor
University of California, San Francisco
Collaborating Sponsor